Alexey S. Shevchuk

Alexey S. Shevchuk

Auto-generated profile, based on publicly available information

Alexey S. Shevchuk

N.N. Blokhin National Medical Research Center of Oncology Pirogov Russian National Research Medical University Moscow, Russian Federation

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2025 in Voprosy onkologii
Verified
Journal Article
Open access
МТМария Николаевна Тихоновская
Мария Николаевна Тихоновская
АШАлексей Сергеевич Шевчук
Алексей Сергеевич Шевчук
РКРостислав Игоревич Князев
Ростислав Игоревич Князев
АРАлексей Александрович Румянцев
Алексей Александрович Румянцев
КАКристина Владимировна Афанасьева
Кристина Владимировна Афанасьева
Введение. Тазовая и парааортальная лимфаденэктомия является обязательным этапом хирургического стадирования при раннем раке яичников. Выявление метастатически пораженных лимфатических узлов потенциально может изменить план лечения пациенток. Однако терапевтическая роль забрюшинной лимфаденэктомии окончательно не определена, при этом выполнение данной процедуры сопряжено с повышенным риском развития интра- и послеоперационных осложнений. Цель. Оценить частоту поражения лимфатических узлов при раннем раке яичников, влияние лимфаденэктомии на изменение плана лечения пациенток, проанализировать осложнения лечения и выживаемость больных. Материалы и методы. Ретроспективный анализ результатов лечения больных раком яичников с клинической I-IIA стадией, которым с 2018 по 2023 г. в отделении онкогинекологии выполнено хирургическое стадирование, включая тазовую и парааортальную лимфаденэктомию. Первичной конечной точкой исследования была частота обнаружения метастазов в лимфатических узлах при раннем раке яичников. Результаты. В исследование включено 99 пациенток. В результате хирургического стадирования выявлены опухолевые клетки в перитонеальной жидкости у 12,1 % пациенток, в неизмененной брюшине таза и латеральных каналов — у 4 %, в маточных трубах — у 4 %, в большом сальнике — у 5,1 %, в контрлатеральном яичнике — у 2 % больных. Частота выявления метастазов в лимфатических узлах составила 7,1 %. 31,3 % пациенток рестадированы в сторону увеличения стадии заболевания, в результате план лечения был изменен у 11,1 % больных. Выявление метастазов в лимфатических узлах не повлияло на изменение плана лечения в отношении назначения стандартной адъювантной химиотерапии в исследуемой группе. Только у одной больной с положительным HRD-статусом метастазы в парааортальных лимфатических узлах явились поводом для назначения поддерживающей терапии PARP-ингибиторами. Общая частота интраоперационных осложнений составила 3 %, послеоперационных — 38,4 %. У 6,1 % пациенток отмечены послеоперационные осложнения тяжелой степени. Прослеженность пациенток составила 96 % при среднем периоде наблюдения 32,1 мес. Безрецидивная выживаемость составила 93,7 %, все прослеженные пациентки на момент анализа живы. Выводы. В изучаемой группе больных клинически ранним раком яичников метастазы в забрюшинных лимфатических узлах в результате выполнения тазовой и парааортальной лимфаденэктомии выявлены в 7,1 % наблюдений. Это не оказало существенного влияния на тактику адъювантной терапии. Для оценки терапевтической роли забрюшинной лимфаденэктомии при раннем раке яичников необходимо проведение проспективных рандомизированных исследований.

6 September 2022 in Surgery and Oncology
Verified
Journal Article
Open access
PDF file
MTM. N. Tikhonovskaya
M. N. Tikhonovskaya
ASA. S. Shevchuk
A. S. Shevchuk
Background. Surgical staging including pelvic and para-aortic lymphadenectomy is recommended in patients with clinical early-stage epithelial ovarian cancer. The therapeutic role of pelvic and para-aortic lymphadenectomy is still under debate, this procedure can increase risk of intra- and post-operative complications. using the sentinel lymph node (SLN) detection in early stage ovarian cancer in very promising and decreases the level of surgical damage. But nowadays the data on effectiveness, safety sensitivity and specificity of SLN are limited and the technique has to be standardized.Aim. To determine the feasibility of the SLN detection procedure using indocyanine green in early stage ovarian cancer.Materials and methods. four patients with clinical stage I epithelial ovarian cancer underwent SLN detection using indocyanine green. The tracer was injected into hilum of the ovary or ovarian ligament stumps in the case of previous adnexectomy. SLN were detected in infrared spectrum. Systemic retroperitoneal lymph node dissection of the pelvic and paraaortic areas was performed after SLN being removed. frozen section of was not performed in this study.Results. SLN were detected in paraaortic area in three of four patients. no one of patients had metastatic disease.Conclusion. The primary experience demonstrates SLN mapping of the ovary being feasible. Prospective study is required to evaluate sensitivity and specificity of SLn detection in early stage ovarian cancer.

17 May 2023 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
ASAlexey S. Shevchuk
Alexey S. Shevchuk
AKAlexander S. Krylov
Alexander S. Krylov
RKRostislav I. Knyazev
Rostislav I. Knyazev
KAKristina V. Afanasieva
Kristina V. Afanasieva
Background. Lymphadenectomy in patients with malignant female genital neoplasms is a necessary step of surgical treatment, the implementation of which allows assessing the the metastatic involvement of the removed lymph nodes and determining indications for postoperative treatment. Sentinel lymph node (SLN) biopsy with ultrastaging method appears to be a good alternative to standard regional lymph node removal with similar long-term oncologic outcomes and significantly lower rates of postoperative complications. Aim. To present the possibility of using a domestic radiopharmaceutical labeled with technetium-99m (Sentiscan) in patients with gynecological cancer. Materials and methods. A series of clinical cases of the use of Sentiscan during SLN biopsy in three patients suffering from cancer of the uterus and vulva is presented. Results. 1824 hours before the operation, 0.4 ml of the prepared solution of radiopharmaceutical 99mTc-Sentiscan with a total activity of 150 MBq was injected into the cervix of the uterus with tumors of the uterine body and into the vulva. After 2 hours, SPECT/CT was performed on the Discovery 670 DR (GE) of the abdomen and pelvis, followed by 3D reconstruction of images for better intraoperative navigation. Intraoperatively, a portable gamma detector Rad Pointer Gamma (Medikor Pharma Ural) was used to identify sentinel lymph nodes. Sentinel lymph nodes were removed in all patients, followed by a control assessment of the gamma radiation level, histological and immunohistochemical studies using panCK, CK18 markers. Conclusion. Presented clinical cases demonstrated high efficacy of sentinel lymph node mapping using radiopharmaceutical Sentiscan. Further studies are necessary for wide implementation of this technology in clinical practice.

15 July 2022 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
ISIvan S. Stilidi
Ivan S. Stilidi
OEOmar A. Egenov
Omar A. Egenov
SNSergey N. Nered
Sergey N. Nered
OKOleksiy E. Kalinin
Oleksiy E. Kalinin
ASAlexey S. Shevchuk
Alexey S. Shevchuk
ТСТюляндина Александра Сергеевна
Тюляндина Александра Сергеевна
Aim. To give a comparative analysis of long-term results of treatment of patients after surgical treatment in combination with systemic chemotherapy with a control group of patients who received only second-line chemotherapy without surgical treatment for recurrent ovarian cancer (OC) with lymph node (LN) involvement, as well as the search of prognostic factors that favorably affect progression-free survival (PFS) and overall survival (OS). Materials and methods. The retrospective analysis included patients under the age of 75 after surgical treatment or after only second-line chemotherapy without surgery for isolated recurrence in the LN or a combined form of recurrence of OC at Blokhin National Medical Research Center of Oncology from 2005 to 2020. All patients had previously received combined treatment for primary OC. Exclusion criteria: absence of LN involvement in the recurrence of OC, primary multiple malignant tumors, relapses of non-epithelial ovarian tumors, the presence of concomitant pathology in the decompensation phase and lack of information about the treatment received for the recurrence of OC and the date of subsequent progression, death or last observation. The primary endpoint of the study is PFS and the secondary endpoint is OS. Results. The final analysis included 214 patients, who were subsequently divided into 2 main groups: the study group consisted of patients (n=123; 57.5%) who underwent repeated cytoreduction + systemic chemotherapy, and the control group included patients (n=91; 42.5%) who received only second-line chemotherapy. In the general population of patients, the median platinum-free interval was 14.0 months. Platinum-sensitive recurrence of OC developed in 88.3% (189/214) of patients, and platinum-resistant recurrence was observed in 11.7% (25/214) of cases. In the study group, complete repeated cytoreduction was achieved in 70.7% (87/123) of patients, and incomplete in 29.3% (36/123) of patients. All 91 patients in the control group received second-line chemotherapy in the planned volume. The vast majority of patients underwent second-line platinum-containing chemotherapy 87.9% (188/214) of patients. The median follow-up was 33.0 (range 0.7174.0) months. Long-term results in the complete cytoreduction group were significantly higher median PFS and OS were 30.0 months and 87.0 months, respectively, however, in the incomplete cytoreduction group, long-term results were statistically significantly worse: median PFS and OS were 10.0 months and 29.0 months versus 12.0 months and 36.0 months, respectively, in the control group of patients. Surgical treatment in combination with chemotherapy for platinum-resistant recurrence of OC did not improve long-term results of treatment: the median PFS was the same in both groups 7.0 months, and the median OS was 24.0 months versus 21.0 months in the control group (p=0.372). Conclusion. Only complete repeated cytoreduction in combination with systemic chemotherapy leads to an improvement in long-term results of treatment compared with incomplete cytoreduction and only second-line systemic chemotherapy. Incomplete repeated cytoreduction, despite combination with systemic chemotherapy, worsens the prognosis and does not improve the results of drug therapy alone in patients with platinum-sensitive recurrence of OC. Combined treatment (surgery + chemotherapy) for platinum-resistant recurrence of OC does not improve long-term results of treatment.

1 October 2025 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
MTM. N. Tikhonovskaya
M. N. Tikhonovskaya
ASA. S. Shevchuk
A. S. Shevchuk
Aim: to evaluate the results of sentinel-lymph-node (SLN) mapping in detecting lymph node metastasis in apparently early-stage ovarian cancer. Material and Methods. The prospective unicentric study included 48 patients with stage I–IIA ovarian cancer who underwent surgical staging at the Department of Gynecological Oncology of N.N. Blokhin National Medical Research Center of Oncology from 2022 to 2024. Patients were injected with indocyanine green dye into the infundibulo-pelvic and utero-ovarian ligaments (or ligament’s stumps) to map and remove sentinel lymph nodes (SLNs). After the SLNs were identified and removed, pelvic and para-aortic lymphadenectomy was performed. Results. Of 48 patients, 40 (83.3 %) had successful mapping of at least one SLN. Three patients (7.5 %) had positive nodes: 1 patient (2.5 %) had metaststic para-aortic SLN; 1 patient (2.5 %) had false-negative para-aortic SLN; and 1 patient (2.5 %) had metastatic pelvic lymph node without SLN detection in this region. Thus, the SLN mapping detection rate was 50 % for metastatic lymph nodes in the para-aortic region. None of the patients with detected SLN in the pelvic region had metastatic lymph nodes. No complications related to SLN technique were observed. Conclusion. The results of this prospective study do not demons trate that lymph nodes status can be fully predicted by SLN evaluation. Further prospective studies are required to evaluate experience of SLN detection in early-stage ovarian cancer.

29 June 2026 in Russian Bulletin of Obstetrician-Gynecologist
Verified
Journal Article
Closed access
MTM.N. Tikhonovskaya
M.N. Tikhonovskaya
ASA.S. Shevchuk
A.S. Shevchuk
AKA.S. Klabukova
A.S. Klabukova
Objective. To evaluate and to compare oncological and reproductive results of hormonal therapy in young women with atypical endometrial hyperplasia (AEH) and early endometrial cancer (EC) according to experience of N.N. Blokhin NMRCO. Methods. Retrospective trial of 84 reproductive age women with AEH and EC (endometrioid grade 1 adenocarcinoma) without myometrial invasion fertility-sparing treated in oncogynecological department of N.N. Blokhin NMRCO from may 2020 to october 2025. EC patients were treated with combination of levonorgestrel intrauterine device (IUD) and gonadotropin-releasing hormone agonist (GnRH). AEH patients were treated with levonorgestrel IUD only. Results. Total of 84 patient were analyzed, AEH (n=26) and EC (n=58). Complete response rate was 100% in AEH and 94.8% in EC. There were no recurrences in AEH group with median follow-up 27.3 (5—47) months. The recurrence rate in EC group was 7.4% with median follow-up 24.5 (1—58) months. The overall conception rate was 21.4%, among them 55.6% with assistant reproductive technologies use. Of total 84 patients 12 (14.3%) delivered successfully. Conclusion. Hormonotherapy of AEH and EC is effective and safe method of fertility-sparing treatment with high probability of conception and delivery.